Cancer Drug News Issue 670

Description: The global expansion of Portrazza will aid in supporting Eli Lilly's lung cancer franchise, but a number of market factors will serve to cap sales well below blockbuster levels. Portrazza is indicative of Eli Lilly's current new product portfolio, which will serve to effectively maintain revenues but not provide high growth levels. The company's innovative pipeline and exploration of novel development routes will serve to bring back notable growth in the long-term.

Contents:
1 Portrazza To Be Modest Contributor To Lilly Revenue Maintenance Haematological Cancer
3 Gazyva FDA-Approved For Previously Treated Follicular Lymphoma Population
3 Ixazomib Granted Orphan Drug Designation In Japan
4 CHMP Recommends Acalabrutinib As Orphan Medicinal Drug For Lymphomas
4 Asterias Concludes End-of-Phase II Meeting With FDA For AST-VAC1 Lung Cancer
4 Peregrine Terminates Bavituximab Phase III SUNRISE Trial
5 First Patients Treated In Tedopi Phase III Advanced NSCLC Trial Genito-Urinary Cancer
5 FDA Accepts sNDA For Xtandi In MCRPCA General Developments
5 FDA Approves Novartis' Afinitor For Non-Functional NETs
6 CHMP Recommends Opdivo And Lonsurf Approvals
6 Unmet Medical Need From Pancreatic Cancer To Grow
8 Growing Cancer Burden To Attract Drugmakers
9 Myriad's Diversification Drive Builds Strong Portfolio Corporate Activity
10 OSE Pharma/Effimune Enter Merger Agreement To Form Immunotherapy Company

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3758138/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct.

Product Name: Cancer Drug News Issue 670
Web Address: http://www.researchandmarkets.com/reports/3758138/
Office Code: SCD23GZ1

Product Format
Please select the product format and quantity you require:

Quantity
Electronic (PDF) - Single User: USD 1252

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World